- Home
- DMAC vs MCR Comparison
DMAC vs MCR Comparison
Compare DMAC & MCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- MCR
- Stock Information
- Founded
- DMAC 2000
- MCR 1989
- Country
- DMAC United States
- MCR United States
- Employees
- DMAC N/A
- MCR N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- MCR Trusts Except Educational Religious and Charitable
- Sector
- DMAC Health Care
- MCR Finance
- Exchange
- DMAC Nasdaq
- MCR Nasdaq
- Market Cap
- DMAC 310.1M
- MCR 265.5M
- IPO Year
- DMAC N/A
- MCR N/A
- Fundamental
- Price
- DMAC $7.06
- MCR $6.33
- Analyst Decision
- DMAC Strong Buy
- MCR
- Analyst Count
- DMAC 3
- MCR 0
- Target Price
- DMAC $12.33
- MCR N/A
- AVG Volume (30 Days)
- DMAC 262.5K
- MCR 66.7K
- Earning Date
- DMAC 11-12-2025
- MCR 01-01-0001
- Dividend Yield
- DMAC N/A
- MCR 8.52%
- EPS Growth
- DMAC N/A
- MCR N/A
- EPS
- DMAC N/A
- MCR 0.38
- Revenue
- DMAC N/A
- MCR N/A
- Revenue This Year
- DMAC N/A
- MCR N/A
- Revenue Next Year
- DMAC N/A
- MCR N/A
- P/E Ratio
- DMAC N/A
- MCR $16.61
- Revenue Growth
- DMAC N/A
- MCR N/A
- 52 Week Low
- DMAC $3.19
- MCR $5.63
- 52 Week High
- DMAC $7.49
- MCR $6.70
- Technical
- Relative Strength Index (RSI)
- DMAC 57.38
- MCR 44.22
- Support Level
- DMAC $6.64
- MCR $6.31
- Resistance Level
- DMAC $7.13
- MCR $6.46
- Average True Range (ATR)
- DMAC 0.27
- MCR 0.07
- MACD
- DMAC -0.00
- MCR -0.00
- Stochastic Oscillator
- DMAC 77.21
- MCR 33.33
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.